scholarly journals End-point Energy Determination of Electron Beams from the Saturn Accelerator 3-Ring Pinched Beam Diode.

2020 ◽  
Author(s):  
Benjamin Ulmen ◽  
Timothy Webb ◽  
Andrew McCourt ◽  
Sean Coffey
Keyword(s):  
Electron Beams ◽  
Point Energy ◽  
End Point ◽  
Energy Determination

7.—Beta-spectra Shape Factors in the Decay of 140La and 72Ga

1972 ◽  
Vol 70 ◽  
pp. 67-74 ◽  
Author(s):  
R. D. Connor ◽  
T. J. Goldman ◽  
I. L. Fairweather
Keyword(s):  
Factor Analysis ◽  
Matrix Element ◽  
Shape Factor ◽  
Shape Factors ◽  
Point Energy ◽  
End Point ◽  
Beta Spectra

SynopsisThe shape factors of the partial β-spectra of highest end-point energy in the decay of 72Ga and 140La have been calculated and compared with the only previously reported determination of these quantities. For both isotopes the shape factor is consonant with the view that the Blj matrix element controls the decay. Shape factor analysis alone is insufficient to determine the cause of the predominance of a particular matrix element.

Determination of theTh235β-decay end point energy

1989 ◽  
Vol 39 (1) ◽  
pp. 256-258
Author(s):  
Yuan Shuanggui ◽  
Zhang Tianmei ◽  
Xu Shuwei ◽  
Li Wenxin ◽  
Zhang Li ◽  
...  
Keyword(s):  
Point Energy ◽  
End Point

scholarly journals KD determination from time-resolved experiments on live cells with LigandTracer and reconciliation with end-point flow cytometry measurements

2021 ◽  
Author(s):  
Diana Spiegelberg ◽  
Jonas Stenberg ◽  
Pascale Richalet ◽  
Marc Vanhove
Keyword(s):  
Flow Cytometry ◽  
Live Cells ◽  
Time Resolved ◽  
Surface Receptors ◽  
Full Characterization ◽  
End Point ◽  
Titration Curves ◽  
Kinetics Of

AbstractDesign of next-generation therapeutics comes with new challenges and emulates technology and methods to meet them. Characterizing the binding of either natural ligands or therapeutic proteins to cell-surface receptors, for which relevant recombinant versions may not exist, represents one of these challenges. Here we report the characterization of the interaction of five different antibody therapeutics (Trastuzumab, Rituximab, Panitumumab, Pertuzumab, and Cetuximab) with their cognate target receptors using LigandTracer. The method offers the advantage of being performed on live cells, alleviating the need for a recombinant source of the receptor. Furthermore, time-resolved measurements, in addition to allowing the determination of the affinity of the studied drug to its target, give access to the binding kinetics thereby providing a full characterization of the system. In this study, we also compared time-resolved LigandTracer data with end-point KD determination from flow cytometry experiments and hypothesize that discrepancies between these two approaches, when they exist, generally come from flow cytometry titration curves being acquired prior to full equilibration of the system. Our data, however, show that knowledge of the kinetics of the interaction allows to reconcile the data obtained by flow cytometry and LigandTracer and demonstrate the complementarity of these two methods.

Sign in / Sign up

Export Citation Format

Share Document